DDInter1274 DDInter704
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Nefazodone {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Nefazodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Nefazodone {u} (Compound) upregulates {v} (Gene) SERPINA3
SERPINA3 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Nefazodone {u} (Compound) downregulates {v} (Gene) TXNDC9
TXNDC9 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Nefazodone {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Everolimus
Nefazodone {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Nefazodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Nefazodone {u} (Compound) upregulates {v} (Gene) SERPINA3
SERPINA3 {u} (Gene) is regulated by {v} (Gene) MTOR
MTOR {u} (Gene) is bound by {v} (Compound) Everolimus
Nefazodone {u} (Compound) upregulates {v} (Gene) NFKBIE
NFKBIE {u} (Gene) is regulated by {v} (Gene) SNRK
SNRK {u} (Gene) is upregulated by {v} (Compound) Everolimus
Nefazodone {u} (Compound) downregulates {v} (Gene) TXNDC9
TXNDC9 {u} (Gene) is regulated by {v} (Gene) SWAP70
SWAP70 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Nefazodone may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Nefazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Nefazodone (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Everolimus (Compound)
Nefazodone (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Everolimus (Compound)
Nefazodone (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Everolimus (Compound)
Nefazodone may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Nefazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Nefazodone (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is regulated by MTOR (Gene) and MTOR (Gene) is bound by Everolimus (Compound)
Nefazodone (Compound) upregulates NFKBIE (Gene) and NFKBIE (Gene) is regulated by SNRK (Gene) and SNRK (Gene) is upregulated by Everolimus (Compound)
Nefazodone (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is regulated by SWAP70 (Gene) and SWAP70 (Gene) is upregulated by Everolimus (Compound)